Johnson & Johnson $JNJ Shares Sold by AGF Management Ltd.

AGF Management Ltd. lowered its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1.2% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 588,745 shares of the company’s stock after selling 7,217 shares during the quarter. AGF Management Ltd.’s holdings in Johnson & Johnson were worth $109,165,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Clayton Financial Group LLC acquired a new stake in shares of Johnson & Johnson in the 3rd quarter worth $28,000. Evolution Wealth Management Inc. purchased a new position in Johnson & Johnson during the second quarter worth about $27,000. Semmax Financial Advisors Inc. lifted its position in Johnson & Johnson by 55.0% in the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock valued at $31,000 after purchasing an additional 72 shares during the period. GFG Capital LLC purchased a new stake in Johnson & Johnson in the 2nd quarter valued at approximately $35,000. Finally, Signature Resources Capital Management LLC increased its position in Johnson & Johnson by 262.9% during the 3rd quarter. Signature Resources Capital Management LLC now owns 254 shares of the company’s stock worth $47,000 after purchasing an additional 184 shares during the period. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Up 1.0%

JNJ stock opened at $233.11 on Wednesday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. Johnson & Johnson has a 12 month low of $141.50 and a 12 month high of $235.20. The firm has a market capitalization of $561.62 billion, a PE ratio of 21.10, a P/E/G ratio of 2.24 and a beta of 0.35. The company’s 50 day simple moving average is $211.74 and its 200-day simple moving average is $192.73.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, January 21st. The company reported $2.46 EPS for the quarter, meeting analysts’ consensus estimates of $2.46. The firm had revenue of $24.56 billion for the quarter, compared to analysts’ expectations of $24.14 billion. Johnson & Johnson had a return on equity of 33.34% and a net margin of 28.46%.Johnson & Johnson’s quarterly revenue was up 9.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.04 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.430-11.630 EPS. Equities analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio is 47.06%.

Analysts Set New Price Targets

JNJ has been the subject of several recent analyst reports. Scotiabank reissued an “outperform” rating on shares of Johnson & Johnson in a report on Thursday, January 22nd. Freedom Capital downgraded Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Friday, January 16th. Royal Bank Of Canada upped their price target on shares of Johnson & Johnson from $240.00 to $255.00 and gave the stock an “outperform” rating in a research note on Tuesday. BMO Capital Markets reissued an “outperform” rating on shares of Johnson & Johnson in a report on Thursday, December 11th. Finally, Morgan Stanley set a $262.00 target price on shares of Johnson & Johnson and gave the company an “overweight” rating in a report on Wednesday, January 28th. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus price target of $233.73.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Multiple analyst upgrades and higher price targets — Morgan Stanley upgraded JNJ to Overweight and raised its PT to $262, RBC lifted its PT to $255 with an Outperform rating, BofA nudged its PT to $227, and other outlets report a PT raised to $265; these moves signal stronger analyst conviction on JNJ’s earnings and margin outlook. Morgan Stanley Upgrades Johnson & Johnson to Overweight, Increases PT to $262 RBC Raises Price Target on Johnson & Johnson to $255 BofA lifts PT on Johnson & Johnson (JNJ) to $227 from $221 – here’s why Johnson & Johnson (NYSE:JNJ) Price Target Raised to $265.00
• Positive Sentiment: MedTech/product progress: J&J MedTech announced updates to its Varipulse product and a new ultrasound catheter, which can expand procedure use and revenue potential in vascular/interventional markets. Johnson & Johnson MedTech announces updates to Varipulse, new ultrasound catheter
• Positive Sentiment: Commercial rollout: J&J launched the first daily-disposable multifocal toric contact lens for astigmatic presbyopic patients in the U.K. and Ireland (ACUVUE®), supporting the consumer/vision revenue stream. Johnson & Johnson Launches the First and Only Daily Disposable Multifocal Toric Contact Lens for Astigmatic Patients with Presbyopia
• Positive Sentiment: Investor access: Management will present at the TD Cowen Health Care Conference on March 3 — a chance to hear updated guidance, pipeline milestones and margin drivers directly from management. Johnson & Johnson to Participate in the TD Cowen 46th Annual Health Care Conference
• Neutral Sentiment: Context piece: A Forbes analysis reviews JNJ’s ~52% run over the past nine months, attributing gains to improved earnings, product wins and legal progress — useful background but not an immediate catalyst. What’s Behind The 50% Surge In JNJ Stock?

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.